Public source
Reviewed 11 May 2026
Completeness Fair (33%)
Paige Prostate Biomarker Panel
PaigePaige Prostate Biomarker Panel detects foci of prostate carcinoma that are likely positive for mutations on digital images from prostate biopsies & resections. If morphological phenotypes consistent with the following mutations are detected, it will classify the sample as positive. Androgen Receptor (AR) amplification: AR Compound tumor suppressor genes alterations, includes alterations in Tumour protein p53 (TP53), Phosphatase and tensin homolog (PTEN), Retinoblastoma protein 1 (RB1).
No papers to support — we monitor for new evidence.
Key features
Disease specific biomarkers
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Staining
Stain subtype
Not specified
Regulatory Information
Pathway:
In Vitro Diagnostic Directive (IVDD)
Class:
General IVD Devices
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
No research papers or evidence on file yet.
The registry monitors publications for new evidence.
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Source: Public | First published: Aug 1, 2025 | Last updated: May 11, 2026